In NSCLC, poor prognosis and chemotherapy resistance were found to be related to the persistent activation of STAT3, and the inhibition of STAT3 activity can effectively inhibit tumor progress 11-13. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.